Sign in to view Stella’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
New York City Metropolitan Area
Contact Info
Sign in to view Stella’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
249 followers
240 connections
Sign in to view Stella’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Stella
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Stella
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Stella’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
About
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Experience & Education
-
EvolveImmune Therapeutics
******** ** ************* ********
-
******, * ****** *******
******-******** **** - ********/***********/***** ******** ***********
-
******** ********** ****** ******* ******
************* **********
View Stella’s full experience
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Publications
View Stella’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Other similar profiles
-
Oksana Sergeeva
Fairfield, CTConnect -
Jay Fine
United StatesConnect -
Antonio Ward, Ph.D.
Watertown, MAConnect -
Jennifer Gabler
New York City Metropolitan AreaConnect -
Michael Franken M.D.
Boston, MAConnect -
Jeremy Myers
Westport, CTConnect -
Amber Fearnley
Research Associate
East Haven, CTConnect -
Mark Aimone, MBA
New York City Metropolitan AreaConnect -
Jeegar Patel, Ph.D.
New York, NYConnect -
Zhanna Polonskaya
Mountainside, NJConnect -
Danielle Klaskin
Senior Research Associate at EvolveImmune Therapeutics
Madison, CTConnect -
Julio Rodriguez
Trying to better the world through research
Hartford, CTConnect -
Xingyue (Amy) An
Senior Scientist@EvolveImmune Therapeutics
United StatesConnect -
Dan Lu
Montvale, NJConnect -
Hemachander Capiralla
Ridgefield, CTConnect -
Mohosin Sarkar
New Haven, CTConnect -
Agnes Meade
New York City Metropolitan AreaConnect -
Tracy Lichter
Research Associate
New Haven, CTConnect -
Afsana Sabrin, PhD
New York, NYConnect -
Stephen Bloch, MD
Westport, CTConnect
Explore more posts
-
Mission Bio
#ICYMI In this on-demand webinar, hear from Robert Bowman, Assistant Professor of Cancer Biology at University of Pennsylvania School of Medicine as he discusses: 💡 How single-cell DNA sequencing provided insights into the mutant-specific alterations involved in leukemic transformation from premalignant clonal hematopoiesis to AML 💡 How single-cell DNA sequencing was leveraged to model sequential mutagenesis and deterministically investigate mechanisms of transformation and oncogenic dependency in the context of clonal evolution 💡 His thoughts and perspective on the importance of building disease models that can recapitulate human disease and how single-cell DNA sequencing can be a useful confirmation tool Watch on-demand anytime ➡ https://lnkd.in/gEv4b7KT #diseasemodels #cancermodels #webinar #singlecell #singlecellanalysis
26
-
uBriGene Biosciences Inc.
🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!
3
-
Anthony Nolan: Cell Therapy and Laboratory Services
New research from the Dana-Farber Cancer Institute has used CRISPR to discover a new potential therapeutic target for the treatment of Acute Myeloid Leukaemia (AML). The researchers used genome-wide CRISPR interference to search for genes involved in AML cell metabolism, and discovered a subset of leukaemic cells that relied on phosphoinositide-3-kinase-gamma (PI3Kγ) signalling for energy production. A PI3Kγ inhibitor already exists – eganelisib – although has not yet been used to treat leukaemia. Here, the researchers effectively shrank AML tumour xenografts with eganelisib, and also found that eganelisib worked even more effectively in combination with the standard AML treatment cytarabine. These findings point towards eganelisib as being an attractive option to improve survival in AML patients, as it is an already existing drug that can be used in combination with cytarabine. The team is now designing a clinical trial to test this. CRISPR is continuing to contribute to major discoveries like this one. At Anthony Nolan, our Immunotherapy Group are investigating potential new cell therapies with the help of technologies like CRISPR. Learn more about how you can work with us: https://lnkd.in/eUX92NSS Read more about the study from the Dana-Farber Cancer Institute: https://lnkd.in/e6CuaMYs #AML #CRISPR
12
-
CTOAM | Cancer Treatment Options & Management
New ADC treatment for heavily pre-treated Small Cell Lung Cancer (SCLC) Watch this video to learn👇 ☑️ What Antibody Drug Conjugates (ADCs) are ☑️ The new treatment that’s showing great results for heavily pre-treated SCLC ☑️ The latest clinical trial on this new protocol and what the results mean ☑️ Additional science-based data and takeaways about the treatment ☑️ Who will likely benefit most from this drug ☑️ How lung cancer patients can find out if this new treatment is right for them ☑️ Next steps to take to access the treatment Precision Oncology specialist, Alex Rolland, discusses how a new ADC treatment for heavily pretreated Small Cell Lung Cancer (SCLC) is helping patients to live far longer and with a much higher quality of life. Alex also shares information on the latest clinical trial done on this new treatment, and the type of patients that it will likely work best for. Click here o watch https://buff.ly/49QKj5g #HopeIsHere #PrecisionCancerMedicine
-
DelveInsight Business Research LLP
Exciting updates from Bristol Myers Squibb on #mezigdomide (#CC92480) in combination with tazemetostat and dexamethasone for multiple myeloma! Mezigdomide, a potent CELMoD under investigation, has shown promising preclinical results, being significantly more potent than #iberdomide and other #IMiDs. In the CA057-003 trial (#NCT05372354), 13 patients who had undergone a median of 5 prior lines of therapy received #mezigdomide, #tazemetostat, and #dexamethasone. The overall response rate (ORR) was 53.8%, with higher mezigdomide doses yielding an ORR of 71.4%. The combination demonstrated a manageable safety profile, with grade 3/4 TEAEs occurring in 69.2% of patients. Notably, mezigdomide rapidly degrades Ikaros and Aiolos proteins, inducing apoptosis in multiple myeloma cells and stimulating the immune system. The future of CELMoDs like mezigdomide looks promising as they continue to show high synergy with traditional partners and advanced treatments. Get detailed analysis of the abstract here @ https://lnkd.in/gd-xFFqy Stay tuned for more updates! #MultipleMyeloma #ClinicalTrials #Mezigdomide #BMS #CancerResearch #CELMoDs #healthcare #business #clinicalstudies #clinicaltrials #results #phases #top #abstracts #myeloma #oncology #pharmacautical #hematology
26
-
Decipher by Veracyte
More than a dozen posters and podium talks were presented at the latest #AUA2024 meeting discussing the power of Veracyte, Inc.'s Decipher Prostate and Bladder tests, as well as our and Decipher GRID (Genomics Resource for Intelligent Discovery) transcriptomic database. Among these was a study discussing that patients with low and intermediate risk #ProstateCancer (GGG 1-3 on initial biopsy), the Decipher Score is a predictor of clinically significant upgrading (i.e, increase in GGG) on final radical prostatectomy pathology. Click the link below to read an overview of this presentation: https://lnkd.in/gRvB8GHv
17
-
RayBiotech
Ever wonder why some CAR-T cell therapies show better efficacy than others? This week's #RayBioRead is a groundbreaking study published in @Nature focused on the role of tonic signaling in CAR-T cell function. The research, led by Chen, J., Qiu, S., Li, W. et al, identifies positively charged patches (PCPs) on CARs as drivers behind spontaneous CAR activation. By manipulating these PCPs, researchers were able to fine-tune CAR-T cell behavior, enhancing effectiveness and reducing exhaustion. This discovery opens doors for next-gen CAR-T designs. Learn more: https://lnkd.in/gxRguPwx Featured RayBiotech Product: https://lnkd.in/e7NdF3-H
2
-
Thomas Bobinski
Reactive Oxygen Species (ROS) play a crucial role in cancer biology, showcasing both tumor-promoting and tumor-suppressing actions. The intricate relationship involves various ROS types such as singlet oxygen, superoxides, peroxides, hydroxyl radical, and hypochlorous acid. These species influence cellular processes, impacting oncogenesis and tumor progression. While ROS can drive cell proliferation and DNA damage, they also induce apoptosis and autophagy as anti-tumorigenic agents at higher levels. The dual functions of ROS in cancer are modulated through distinct signaling pathways. For instance, ROS activate oncogenic pathways like Ras-Raf-MEK1/2-ERK1/2, alongside contributing to cancer suppression via the p38 MAPK pathway. The balance between these pathways and ROS concentrations dictates their overall effect on tumorigenesis. It is essential to recognize that ROS effects on cancer are context-specific, dependent on ROS levels, cell molecular background, and involved signaling pathways. Understanding the bidirectional impacts of ROS is pivotal for tailored cancer therapies and potential antioxidant use in cancer treatment. The nuanced nature of ROS in cancer underscores the importance of precise targeting and careful consideration when applying antioxidant strategies. For an in-depth exploration, refer to the article: https://lnkd.in/gB_M-QRH #ReactiveOxygenSpecies #ROS #CancerBiology #TumorProgression #CellularProcesses
6
1 Comment -
CRB
Imagine a molecule capable of delivering deadly toxins directly to pathogens or cancer cells. With antibody-drug conjugates (ADCs), it’s possible. Ashley Harp dives into the basics of ADCs, their function, and the technologies used to manufacture them in her latest Insights blog. Learn more: https://hubs.la/Q02xXZxM0 #LifeSciences #ADC #AntibodyDrugConjugates #CRBInsights
76
2 Comments -
Center for Technology Licensing at Cornell University (CTL)
⏰ Event Reminder Join us for CTL@WCM special panel discussion on "Leveraging Alternatives to Animal Models to Transform Drug Development"! this Thursday, May 30th, 2024 🔍 Discover how novel human model systems like organoids and in silico platforms are transforming drug development. Learn about their potential to replace traditional animal models and the challenges ahead. 🔗 https://ow.ly/ejYf50RY26Y
2
-
Ludwig Cancer Research
Ludwig Lausanne's Melita Irving, recent PhD graduate Evangelos Stefanidis and colleagues report in the Journal of Clinical Investigation a novel two-pronged immunotherapy strategy to simultaneously drive T cell and macrophage attack on tumors. Their approach modifies T cells equipped with affinity optimized T cell receptors to additionally secrete a factor that stimulates macrophage attack on cancer cells. This approach, combined with clinical antibodies like Avelumab and Cetuximab, significantly boosts the immune system's ability to eliminate cancer cells. This study also highlights the complexities of cancer immunotherapy and the need for nuanced therapeutic strategies. https://bit.ly/3X4fjMb
52
3 Comments -
Charles River Associates
Oncologists recently gathered at #ASCO2024 to discuss the latest in cancer research, with a major focus on biomarkers and antibody-drug conjugates (ADCs). Highlights included groundbreaking trial data for small molecules like Lorbrena and Tagrisso, emphasizing the effectiveness of targeted biomarker therapies. Notable advancements in biomarker technologies and individualized neoantigen therapies were also showcased, alongside challenges in ADC efficacy and safety. Future discussions will explore new biomarker detection methods and multitarget ADCs to enhance specificity and reduce side effects. To read the full CRA Insights by Aaron E., click here: https://crai.news/a88 #CRALifeSciences
13
-
Leukaemia UK
Dana-Farber researchers discover new target for potential leukaemia therapy Dana-Farber Cancer Institute scientists have found a new target for leukaemia treatment. They discovered that some leukaemias depend on a complex called PI3Kgamma to survive. Excitingly, an existing drug, eganelisib, can inhibit this complex. Using an existing drug means animal models have already been tested, showing promise when using a combination therapy approach. Clinical trials for this new approach could start soon, offering hope for better leukaemia treatments. https://lnkd.in/g3A4A3ZZ
10
-
AJMC - The American Journal of Managed Care
A panel of experts, led by Ryan Haumschild PharmD, MS, MBA, CPEL, discuss the impact chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have on patient quality of life and explore current treatment strategies in CLL and SLL management. Watch the series here: https://bit.ly/4aXuhr2 #CancerCare
5
-
Entos Pharmaceuticals
It’s been a very informative day of discussions, networking, and debates for Entos Pharmaceuticals Scientists Silke Andresen and Brendan Todd, Ph.D. at the Drug Discovery Biology & Bioinformatics West Coast Strategy Meeting in San Diego. Want to continue the conversation? Send Silk and Brendan a DM to meet and chat! #ProventaStrategyMeetings #Networking #BioInformatics #IndustryInsights #pharmaceuticals #lifesciences #researchanddevelopment
61
-
Quantum Regulatory Solutions, LLC
Part 2 of a two-part post: Advanced Therapies! We recently sat down with Head of Advanced Therapies, Kevin Hennegan, to discuss Quantum's advanced therapies support for Sponsors. Check out Kevin's responses below: 3. What are some keys to building a successful engagement with a regulatory advisor in the Advanced Therapy space? Start by assessing whether the individual or group you are considering is a good fit with your existing team. Arrange for introductory or interview calls between the candidate and the members of your team who will be working with them directly. This shouldn’t be as involved as the interview process for an FTE role, but it may be in the same ballpark. You want to find someone who is a good fit with your company culture and the individual personalities within your team. You should also evaluate the individual’s depth of experience, but don’t be too quick to dismiss someone who doesn’t fit perfectly within your company’s niche specialty. In my experience, a broad background within the product’s therapeutic class has been more important than a precise match with a specific clinical indication. Finally, work to incorporate your advisor as an integral part of your development team. Sure, a regulatory strategist can write a memo or risk assessment for you, then ride off into the sunset until the next time you call, but they will be more effective, and you will reap greater benefits, if they are aware of and engaged in updates on the development process as they happen. 4. Why did you decide to bring your skill sets to Quantum? I have known and worked with two of Quantum’s founders for many years now (and am really enjoying getting to know the third). Because of that shared history, I knew the kind of environment they would build within their new company, I knew the caliber of experts they would bring to the table to support product development, and most importantly for me, I knew that we had a uniquely complementary and synergistic fit of personalities, skill sets, and knowledge bases. So, when they offered me the chance to head up their Advanced Therapies practice, I jumped at it. I find the Cell & Gene Therapy space incredibly interesting and exciting. I am thrilled to be a part of the team here!
12
-
The Scientist
Drug development for treating ALS requires an understanding of how genetic mutations lead to the ALS phenotype. Learn more from bit.bio about how scientists can quickly generate human-relevant cell models for functional assays for ALS drug discovery. #AD Click the link below to learn more: https://ow.ly/zXtn50RKGlR
3
-
Childhood Cancer Data Lab
The preprint for the Single-cell Pediatric Cancer Atlas (ScPCA) is now available! Read about this data resource, which holds uniformly processed single-cell and single-nuclei RNA-sequencing data and de-identified metadata from pediatric tumor samples. Originally comprised of data from 10 projects funded by Alex's Lemonade Stand Foundation, the ScPCA Portal currently has more than 500 samples from over 50 types of cancer from ALSF-funded and community-contributed datasets. More ScPCA news: -We have just launched the OpenScPCA project! This project aims to collaboratively analyze the ScPCA data and is designed to allow experts worldwide to contribute. Learn more at openscpca.readthedocs.io. -If you're interested in OpenScPCA, check out our upcoming workshop! This 2-day course will cover reproducible research practices and how to contribute to the project. Join us on May 14-15 in Philadelphia. Learn more! >> https://lnkd.in/e8fAnEFM
14
-
Vesiculab
An in-depth overview of extracellular vesicle biology in Caenorhabditis elegans: in this comprehensive literature review, Juan Wang, Maureen Barr at Rutgers University and Ann Wehman at University of Denver summarised key themes that have emerged for C. elegans EVs and their relevance to human health and disease https://lnkd.in/eabPWYmN The authors also highlighted the diversity of biogenesis mechanisms, locations, and functions of worm EVs. #extracellularvesicles #exosomes #biogenesis #microvesicles #Vesiculab
48
1 Comment
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More